Marquette Asset Management LLC Makes New $116,000 Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Marquette Asset Management LLC acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 20,860 shares of the company’s stock, valued at approximately $116,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. State Street Corp lifted its stake in 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after buying an additional 37,232 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after acquiring an additional 1,087,147 shares during the period. Novo Holdings A S lifted its position in 4D Molecular Therapeutics by 7.1% in the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after acquiring an additional 100,000 shares in the last quarter. Redmile Group LLC boosted its stake in 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after purchasing an additional 188,655 shares during the period. Finally, Braidwell LP increased its holdings in 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on FDMT shares. Morgan Stanley reduced their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday. Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Chardan Capital restated a “buy” rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, Leerink Partners decreased their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.56.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $4.88 on Wednesday. The company has a fifty day moving average price of $6.87 and a two-hundred day moving average price of $11.77. 4D Molecular Therapeutics, Inc. has a one year low of $4.68 and a one year high of $36.25. The stock has a market cap of $225.59 million, a P/E ratio of -1.71 and a beta of 2.81.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.